---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-052235"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:43:44.176472+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions appoints Tony J. Hunt (Repligen Chairman) to board effective Jan 2, 2025

## Summary
- Tony J. Hunt, Executive Chairman of Repligen (Nasdaq: RGEN), appointed to BioLife board.
- Appointment increases board size to six members; Hunt qualifies as independent under Nasdaq rules.
- Hunt previously served as Repligen CEO (2015-2024) and President of Bioproduction at Life Technologies.
- He will serve on the Audit Committee and receive standard non-employee director compensation.
- Board cites Hunt's bioprocessing expertise to support BioLife's focus on cell and gene therapy tools.

## SEC filing metadata
- accession: 0001628280-24-052235
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828024052235/0001628280-24-052235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828024052235/blfs-20241216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-052235
- JSON: https://secwatch.observer/filing/0001628280-24-052235.json
- Plain text: https://secwatch.observer/filing/0001628280-24-052235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.